Letter: In brief (1)

November 9, 2001

Your article on rational drug design (Features: research, THES , October 26) gave a good summary of current thinking about chemical modelling, given increasing costs in moving drugs through the development process. Only a small percentage of drugs make it from the laboratory bench to preclinical or phase-one trials, let alone go on to be proved efficacious and end up on the pharmacists' shelf.

Mark Lipscombe
Project manager
Origin Pharmaceutical Services Ltd

Please login or register to read this article.

Register to continue

Get a month's unlimited access to THE content online. Just register and complete your career summary.

Registration is free and only takes a moment. Once registered you can read a total of 3 articles each month, plus:

  • Sign up for the editor's highlights
  • Receive World University Rankings news first
  • Get job alerts, shortlist jobs and save job searches
  • Participate in reader discussions and post comments

Have your say

Log in or register to post comments